Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma

Official title

Phase III Study of Adjuvant Pembrolizumab vs Active Surveillance After Nephrectomy in Patients With Non-Clear Cell Renal-Cell Carcinoma

Overview

This phase III trial compares the effect of pembrolizumab to active surveillance after a surgical procedure to completely or partially remove a kidney (nephrectomy) in improving time without disease in patients with non-clear cell renal cell cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after nephrectomy may be more effective than the usual active surveillance approach for improving time without disease in patients with non-clear cell renal cell cancer.

Detailed description

PRIMARY OBJECTIVE:

I. To evaluate whether adjuvant treatment of pembrolizumab will lead to better disease-free survival (DFS) compared to patients receiving no adjuvant treatment in the active surveillance arm.

SECONDARY OBJECTIVES:

I. To compare overall survival (OS) between patients receiving pembrolizumab versus (vs.) active surveillance II. To assess the safety and tolerability in each arm. III. To compare DFS between patients randomized to the pembrolizumab arm vs. the active surveillance arm in patients that are circulating tumor deoxyribonucleic acid (ctDNA) positive at baseline.

IV. To compare OS between patients randomized to the pembrolizumab arm vs. the active surveillance arm in patients that are ctDNA positive at baseline.

V. To compare the percentage of baseline ctDNA positive patients that achieve ctDNA clearance at week 12 between the pembrolizumab arm and active surveillance arm at.

VI. To compare DFS with KIM-1 status (high and low) by treatment arms. VII. To assess whether a decrease in KIM-1 after one cycle of adjuvant therapy is associated with improved DFS among patients receiving pembrolizumab.

VIII. To evaluate whether an increase in KIM 1 at predefined landmark timepoints is associated with an increased risk of subsequent DFS events.

IX. To evaluate whether persistently elevated C-reactive protein (CRP) is associated with recurrence.

EXPLORATORY OBJECTIVE:

I. To assess DFS and OS in each histology subgroups (papillary, chromophobe, unclassified, other).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo active surveillance, including computed tomography (CT) or magnetic resonance imaging (MRI), every 3 months for 1 year. Patients also undergo collection of blood samples on study and CT or MRI during follow up. Patients may undergo echocardiography (ECHO) and/or bone scan and/or positron emission tomography (PET)/CT if clinically indicated.

ARM B: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the trial and collection of blood samples on study. Patients may undergo ECHO and/or bone scan and/or PET/CT if clinically indicated.

After completion of study treatment, patients are followed up every 3 months up to year 2, every 6 months in years 2-5, and every 12 months in years 5-10.

Interventions

• Procedure Biospecimen Collection
  Undergo collection of blood samples
• Procedure Bone Scan
  Undergo bone scan
• Procedure Computed Tomography
  Undergo CT and PET/CT
• Procedure Echocardiography Test
  Undergo ECHO
• Procedure Magnetic Resonance Imaging
  Undergo MRI
• Other Patient Observation
  Undergo active surveillance
• Biological Pembrolizumab
  Given IV
• Procedure Positron Emission Tomography
  Undergo PET/CT

Primary outcome measures

• Disease-free survival (DFS) [Time frame: From randomization to first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first, assessed up to 10 years]

Secondary outcome measures (9)

• Overall survival (OS) [Time frame: From randomization to death from any cause, assessed up to 10 years]
• Incidence of adverse events [Time frame: Up to 1 year]
• DFS among those that are circulating tumor deoxyribonucleic acid (ctDNA) positive [Time frame: Up to 10 years]
• OS among those that are ctDNA positive [Time frame: Up to 10 years]
• ctDNA clearance rate prediction [Time frame: At week 12]
• DFS by KIM-1 status [Time frame: Up to 10 years]
• DFS by KIM-1 in pembrolizumab arm [Time frame: Post-cycle 1 (cycle length = 6 weeks)]
• DFS in patients with any KIM-1 increase and not [Time frame: Up to 10 years]
• Recurrence rate in C-reactive protein (CRP) groups [Time frame: Up to 10 years]

Eligibility criteria

Inclusion criteria

• Patient must be ≥ 18 years of age
• Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Patient must have histologically confirmed non-clear cell renal cell carcinoma (nccRCC) with ≥ pT3Nx or pTanyN+ or pTanyNanyM1 with no evidence of disease (NED) per the American Joint Committee on Cancer (AJCC) 8th edition
• Patient must not have renal medullary carcinoma
• Patient must have had a partial or radical nephrectomy. In the case of patients with M1 NED status, a complete resection of the metastatic lesion(s) (metastasectomy) must have been completed at the time of nephrectomy or within 1 year after nephrectomy

• Positive margins are allowed as long as no gross disease
• Patient must not have residual thrombus post nephrectomy in the vena renalis or vena cava
• Patient must be randomized ≤ 16 weeks after nephrectomy and/or < 16 weeks after metastasectomy
• Patient must have undergone imaging of chest, abdomen and pelvis with a CT or MRI after nephrectomy/metastasectomy and within 42 days prior to randomization documenting there is no evidence of liver, bone, or brain metastases
• Patient must not have received any prior anti-PD-1/PD-L1 or CTLA-4 agents
• Patient must not have received any prior radiotherapy for nccRCC
• Patient must not have received prior systemic treatment for nccRCC (except nephrectomy or metastasectomy). Patient must not have received prior immune checkpoint inhibitor agents for other cancers within 2 years prior to randomization
• Patient must not have active known or suspected autoimmune disease requiring systemic immunosuppression. The following autoimmune disorders are permitted: patients with vitiligo, type I diabetes mellitus, controlled/stable hypo or hyperthyroidism due to autoimmune or non-autoimmune conditions (hormone replacement is allowed), psoriasis not requiring systemic treatment
• Patient must not be on any immunosuppressant therapy other than inhaled steroids, intranasal steroids, topical steroids, injection steroids and systemic steroids up to 10mg prednisone equivalent
• Patient must have recovered adequately from toxicity and/or complications related to any surgery received prior to randomization
• Patient must not have a history or current evidence of uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase the risk of incurring adverse events (AEs), or compromise the ability of the patient to give written informed consent
• Patient must not have had a history of allogeneic organ transplantation
• Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used

• All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy
• A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
• Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential assigned to Arm B must continue contraception requirements for 4 months following the last dose of pembrolizumab. Patients assigned to Arm B must also not breastfeed while on protocol treatment and for 4 months after the last dose of pembrolizumab
• Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
• Leukocytes ≥ 3,000/ mm\^3 (must be obtained ≤ 42 days prior to protocol randomization)
• Absolute neutrophil count (ANC) ≥ 1,500/mm\^3 (must be obtained ≤ 42 days prior to protocol randomization)
• Platelets ≥ 100,000/ mm\^3 (must be obtained ≤ 42 days prior to protocol randomization)
• Total bilirubin ≤ 2 x institutional upper limit of normal (ULN) (must be obtained ≤ 42 days prior to protocol randomization)

• NOTE: For patients with known Gilbert's syndrome, total bilirubin < 3 x ULN
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3.0 × institutional ULN (must be obtained ≤ 42 days prior to protocol randomization)
• Estimated glomerular filtration rate (eGFR) clearance ≥ 30 mL/min/1.73 m\^2 (must be obtained ≤ 42 days prior to protocol randomization)
• Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
• For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
• Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
• Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
• Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients must be class 2 or better

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07689240 · NCI-2026-04730 · NCI-2026-04730 · EA8252 · EA8252 · U10CA180820

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗